Elucidation of binding mode and three dimensional quantitative structure-activity relationship studies of a novel series of protein kinase B/Akt inhibitors

Journal of Molecular Modeling

Volumn 15, Issue 2, 2009, Pages 183-192

  Muddassar, M ^a,b   Pasha, F A ^a   Neaz, M M ^a,b   Saleem, Y ^a,b   Cho, S J ^a,c  

^a Korea Institute of Science and Technology   (South Korea)

^b University of Science and Technology (UST)   (South Korea)

^c Chosun University   (South Korea)

Author keywords

3D QSAR; Inhibitors; Molecular docking; Protein kinase B

Indexed keywords

ADENOSINE TRIPHOSPHATE; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR;

ARTICLE; COMPARATIVE MOLECULAR FIELD ANALYSIS; COMPARATIVE MOLECULAR SIMILARITY INDICES ANALYSIS; COMPUTER PROGRAM; DRUG ACTIVITY; DRUG BINDING; DRUG DESIGN; DRUG SELECTIVITY; DRUG STRUCTURE; HYDROGEN BOND; HYDROPHOBICITY; LIGAND BINDING; MOLECULAR DOCKING; PRIORITY JOURNAL; QUANTITATIVE STUDY; STRUCTURE ACTIVITY RELATION;

HUMANS; IMAGING, THREE-DIMENSIONAL; MOLECULAR CONFORMATION; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 58549120356     PISSN: 16102940     EISSN: 09485023     Source Type: Journal    
DOI: 10.1007/s00894-008-0416-7     Document Type: Article

References (30)

1. Hemmings BA (1997) Akt signaling: Linking membrane events to life and death decisions. Science 275:628-630. doi: 10.1126/science.275.5300.628
2. Burgering BM, Coffer PJ (1995) Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature 376:599-602. doi: 10.1038/376599a0
3. Nakatani K, Sakaue H, Thompson DA, Weigel RJ, Roth RA (1999) Identification of a human Akt3 (protein kinase B gamma) which contains the regulatory serine phosphorylation site. Biochem Biophys Res Commun 257:906-910. doi: 10.1006/bbrc.1999.0559
4. Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P et al (1996) Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J 15:6541-6551
5. Galetic I, Andjelkovic M, Meier R, Brodbeck D, Park J, Hemmings BA (1999) Mechanism of protein kinase B activation by insulin/insulin-like growth factor-1 revealed by specific inhibitors of phosphoinositide 3-kinase-significance for diabetes and cancer. Pharmacol Ther 82:409-425. doi: 10.1016/S0163-7258(98)00071-0
6. Yoganathan TN, Costello P, Chen X, Jabali M, Yan J, Leung D et al (2000) Integrin-linked kinase (ILK): A "hot" therapeutic target. Biochem Pharmacol 60:1115-1119. doi: 10.1016/S0006-2952(00)00444-5
7. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S et al (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304:554. doi: 10.1126/science.1096502
8. Workman P, Clarke PA, Guillard S, Raynaud FI (2006) Drugging the PI3 kinome. Nat Biotechnol 24:794-796. doi: 10.1038/nbt0706-794
9. Hisamoto K, Ohmichi M, Kurachi H, Hayakawa J, Kanda Y, Nishio Y et al (2001) Estrogen induces the Akt-dependent activation of endothelial nitric-oxide synthase in vascular endothelial cells. J Biol Chem 276:3459-3467. doi: 10.1074/jbc.M005036200
10. Jeong SJ, Dasgupta A, Jung KJ, Um JH, Burke A, Park HU et al (2008) PI3K/ AKT inhibition induces caspase-dependent apoptosis in HTLV-1-transformed cells. Virology 370:264-272. doi: 10.1016/j.virol.2007.09.003
11. Zhao Z, Leister WH, Robinson RG, Barnett SF, Defeo-Jones D, Jones RE et al (2005) Discovery of 2,3,5-trisubstituted pyridine derivatives as potent Akt1 and Akt2 dual inhibitors. Bioorg Med Chem Lett 15:905-909. doi: 10.1016/j.bmcl.2004.12.062
12. Lindsley CW, Zhao Z, Leister WH, Robinson RG, Barnett SF, Defeo-Jones D et al (2005) Allosteric Akt (PKB) inhibitors: Discovery and SAR of isozyme selective inhibitors. Bioorg Med Chem Lett 15:761-764. doi: 10.1016/j.bmcl.2004.11.011
13. Pasha FA, Muddassar M, Cho SJ, Ahmad K, Beg Y (2008) 3D and quantum QSAR of non-benzodiazepine compounds. Eur J Med Chem (2008) 43:2361-2372
14. Pasha FA, Neaz MM, Cho SJ, Kang SB (2007) Quantitative structure activity relationship (QSAR) study of estrogen derivatives based on descriptors of energy and softness. Chem Biol Drug Des 70:520-529. doi: 10.1111/j.1747-0285.2007.00593.x
15. Marshall GR, Cramer RD 3rd (1988) Three-dimensional structure-activity relationships. Trends Pharmacol Sci 9:285-289. doi: 10.1016/ 0165-6147(88)90012-0
16. Muddassar M, Pasha FA, Chung HW, Yoo KH, Oh CH, Cho SJ (2008) Receptor guided 3D-QSAR: A useful approach for designing of IGF-1R inhibitors. J Biomed Biotechnol 2008:837653. doi: 10.1155/2008/837653
17. Zhu GD, Gong J, Gandhi VB, Woods K, Luo Y, Liu X et al (2007) Design and synthesis of pyridine-pyrazolopyridine-based inhibitors of protein kinase B/Akt. Bioorg Med Chem 15:2441-2452. doi: 10.1016/ j.bmc.2007.01.010
18. Zhu GD, Gandhi VB, Gong J, Thomas S, Woods KW, Song X et al (2007) Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase b/akt inhibitors with reduced hypotension. J Med Chem 50:2990-3003. doi: 10.1021/jm0701019
19. Clark M, Cramer RD, Vanopdenbosch N (1989) Validation of the general-purpose tripos 5.2 force-field. J Comput Chem 10:982-1012. doi: 10.1002/jcc.540100804
20. Rarey M, Kramer B, Lengauer T, Klebe G (1996) A fast flexible docking method using an incremental construction algorithm. J Mol Biol 261:470-489. doi: 10.1006/jmbi.1996.0477
21. Zou XJ, Lai LH, Jin GY, Zhang ZX (2002) Synthesis, fungicidal activity, and 3D-QSAR of pyridazinone-substituted 1,3,4-oxadiazoles and 1,3,4-thiadiazoles. J Agric Food Chem 50:3757-3760. doi: 10.1021/ jf0201677
22. Klebe G, Abraham U, Mietzner T (1994) Molecular similarity indexes in a comparative-analysis (Comsia) of drug molecules to correlate and predict their biological-activity. J Med Chem 37:4130-4146. doi: 10.1021/ jm00050a010
23. Geladi P, Xie YL, Polissar A, Hopke P (1998) Regression on parameters from three-way decomposition. J Chemometr 12:337-354. doi: 10.1002/ (SICI)1099-128X(199809/10)12:5<337::AID-CEM517>3.0.CO;2-1
24. Cramer RD, Bunce JD, Patterson DE, Frank IE (1988) Cross-validation, bootstrapping, and partial least-squares compared with multiple-regression in conventional qsar studies. Quant Struct Activity Relationships 7:18-25. doi: 10.1002/qsar.19880070105
25. Gassel M, Breitenlechner CB, Ruger P, Jucknischke U, Schneider T, Huber R et al (2003) Mutants of protein kinase A that mimic the ATP-binding site of protein kinase B (AKT). J Mol Biol 329:1021-1034. doi: 10.1016/ S0022-2836(03)00518-7
26. Yang J, Cron P, Thompson V, Good VM, Hess D, Hemmings BA et al (2002) Molecular mechanism for the regulation of protein kinase B/Akt by hydrophobic motif phosphorylation. Mol Cell 9:1227-1240. doi: 10.1016/ S1097-2765(02)00550-6
27. Davies TG, Verdonk ML, Graham B, Saalau-Bethell S, Hamlett CC, McHardy T et al (2007) A structural comparison of inhibitor binding to PKB, PKA and PKA-PKB chimera. J Mol Biol 367:882-894. doi: 10.1016/ j.jmb.2007.01.004
28. Bang SJ, Cho SJ (2004) Comparative molecular field analysis (CoMFA) and comparative molecular similarity index analysis (CoMSIA) study of mutagen X. Bull Korean Chem Soc 25:1525-1530
29. Liao CZ, Xie AH, Zhou JJ, Shi LM, Li ZB, Lu XP 3rd (2004) QSAR studies on peroxisome proliferator-activated receptor gamma agonists using CoMFA and CoMSIA. J Mol Model 10:165-177. doi: 10.1007/s00894-003-0175-4
30. Ekins S, Waller CL, Swaan PW, Cruciani G, Wrighton SA, Wikel JH (2000) Progress in predicting human ADME parameters in silico. J Pharmacol Toxicol Methods 44:251-272. doi: 10.1016/S1056-8719(00)00109-X